Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study - PubMed (original) (raw)
Multicenter Study
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA. 2003.
Abstract
Context: The Diabetes Control and Complications Trial (DCCT) demonstrated the benefits of intensive treatment of diabetes in reducing glycemic levels and slowing the progression of diabetic nephropathy. The DCCT cohort has been examined annually for another 8 years as part of the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. During the EDIC study, glycemic levels no longer differed substantially between the 2 original treatment groups.
Objective: To determine the long-term effects of intensive vs conventional diabetes treatment during the DCCT on kidney function during the EDIC study.
Design, setting, and participants: Observational study begun in 1993 (following DCCT closeout) in 28 medical centers in the United States and Canada. Participants were 1349 (of 1375) EDIC volunteers who had kidney evaluation at years 7 or 8.
Main outcome measures: Development of microalbuminuria, clinical-grade albuminuria, hypertension, or increase in serum creatinine level.
Results: Results were analyzed by intention-to-treat analyses, comparing the 2 original DCCT treatment groups. New cases of microalbuminuria occurred during the EDIC study in 39 (6.8%) of the participants originally assigned to the intensive-treatment group vs 87 (15.8%) of those assigned to the conventional-treatment group, for a 59% (95% confidence interval [CI], 39%-73%) reduction in odds, adjusted for baseline values, compared with a 59% (95% CI, 36%-74%) reduction at the end of the DCCT (P<.001 for both comparisons). New cases of clinical albuminuria occurred in 9 (1.4%) of the participants in the original intensive-treatment group vs 59 (9.4%) of those in the original conventional-treatment group, representing an 84% reduction in odds (95% CI, 67%-92%), compared with a reduction of 57% (95% CI, -1% to +81%) at the end of the DCCT. Fewer cases of hypertension (prevalence at year 8, 29.9% vs 40.3%; P<.001) developed in the original intensive-treatment group. Significantly fewer participants reached a serum creatinine level of 2 mg/dL or greater in the intensive-treatment vs the conventional-treatment group (5 vs 19, P =.004), but there were no differences in mean log clearance values. Although small numbers of patients required dialysis and/or transplantation, fewer patients experienced either of these outcomes in the intensive group (4 vs 7, P =.36).
Conclusions: The persistent beneficial effects on albumin excretion and the reduced incidence of hypertension 7 to 8 years after the end of the DCCT suggest that previous intensive treatment of diabetes with near-normal glycemia during the DCCT has an extended benefit in delaying progression of diabetic nephropathy.
Figures
Figure 1
Distribution of HbA1c Concentration by Randomized Treatment Group at the End of the DCCT and in Each Year of the EDlC Study DCCT indicates Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications; HbA1c, glycosylated hemoglobin. Boxes indicate 25th and 75th percentiles of HbA1c, level; whiskers, 5th and 95th percentiles; heavy horizontal lines, medians; thin horizontal lines, means.
Figure 2
Prevalence and Cumulative Incidence of Microalbuminuria Microalbuminuria defined as albumin excretion rate ≥28 μg/min, equivalent to 40 mg/24 h. A, Prevalence at the end of the Diabetes Control and Complications Trial (DCCT) and during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. The differences between the 2 treatment groups are significant at each time point after DCCT closeout (P<.001). B, Cumulative incidence of new cases in the EDIC study for those participants in the intensive- and conventional-treatment groups with normal albuminuria at the beginning and end of the DCCT. The difference in cumulative incidences is significant by the log-rank test (P<.001).
Figure 3
Prevalence and Incidence of Albuminuria Albuminuria defined as albumin excretion rate ≥208 μg/min, equivalent to 300 mg/24 h. A, Prevalence of clinical albuminuria at the end of the Diabetes Control and Complications Trial (DCCT) and during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. The differences between the treatment groups are significant at each time point after DCCT close-out (P<.01). B, Cumulative incidence of new cases in the EDIC study for those participants in the intensive- and conventional-treatment groups with either normoalburninuria or microalbuminuria at the end of the DCCT. The difference in cumulative incidences is significant by the tog-rank-test. (P<.001).
Figure 4
Prevalence of Hypertension at Each Year of the EDlC Study Prevalence of hypertension (defined as blood pressure >140/90 mm Hg) at the end of the Diabetes Control and Complications Trial (DCCT) and during the Epidemiology of Diabetes Interventions and Comptications (EDIC) study for participants in the intensive- vs conventional-treatment groups. The aggregate odds reduction with intensive vs conventional therapy of emergent hypertension during the EDIC study, adjusted for DCCT mean arterial pressure, was 40.4% (95% confidence interval, 33.7%-46.5%; P<.001).
Similar articles
- Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.
DCCT/EDIC research group. Lancet Diabetes Endocrinol. 2014 Oct;2(10):793-800. doi: 10.1016/S2213-8587(14)70155-X. Epub 2014 Jul 17. Lancet Diabetes Endocrinol. 2014. PMID: 25043685 Free PMC article. Clinical Trial. - Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Diabetes Care. 1999 Jan;22(1):99-111. doi: 10.2337/diacare.22.1.99. Diabetes Care. 1999. PMID: 10333910 Free PMC article. - Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
de Boer IH; DCCT/EDIC Research Group. de Boer IH, et al. Diabetes Care. 2014;37(1):24-30. doi: 10.2337/dc13-2113. Diabetes Care. 2014. PMID: 24356594 Free PMC article. Clinical Trial. - Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Fullerton B, et al. Cochrane Database Syst Rev. 2014 Feb 14;2014(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Cochrane Database Syst Rev. 2014. PMID: 24526393 Free PMC article. Review. - Kidney Disease in Diabetes.
Pavkov ME, Collins AJ, Coresh J, Nelson RG. Pavkov ME, et al. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 22. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 22. PMID: 33651560 Free Books & Documents. Review.
Cited by
- Causal association between antidiabetic drugs and erectile dysfunction: evidence from Mendelian randomization.
Feng L, Jinhua W, Shulin G, Jiangping X, Zhongxiang L, Xiaohong L. Feng L, et al. Front Endocrinol (Lausanne). 2024 Aug 23;15:1414958. doi: 10.3389/fendo.2024.1414958. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39247921 Free PMC article. - Clinical relevance of short-term glycemic variability in children and adolescents with type 1 diabetes: a narrative review.
Bombaci B, Passanisi S, Lombardo F, Salzano G. Bombaci B, et al. Transl Pediatr. 2024 Jul 31;13(7):1231-1241. doi: 10.21037/tp-24-114. Epub 2024 Jul 16. Transl Pediatr. 2024. PMID: 39144438 Free PMC article. Review. - Cardiovascular Risks in Adolescents With Diabetes From Vulnerable Populations.
Faulkner MS, Fritschi C, Quinn L, Hepworth JT. Faulkner MS, et al. Home Health Care Manag Pract. 2010 Feb;22(2):123-130. doi: 10.1177/1084822309343944. Epub 2009 Nov 6. Home Health Care Manag Pract. 2010. PMID: 39055335 Free PMC article. - Diabetes Telemedicine Mediterranean Diet (DiaTeleMed) Study: study protocol for a fully remote randomized clinical trial evaluating personalized dietary management in individuals with type 2 diabetes.
Berube LT, Popp CJ, Curran M, Hu L, Pompeii ML, Barua S, Bernstein E, Salcedo V, Li H, St-Jules DE, Segal E, Bergman M, Williams NJ, Sevick MA. Berube LT, et al. Trials. 2024 Jul 25;25(1):506. doi: 10.1186/s13063-024-08337-w. Trials. 2024. PMID: 39049121 Free PMC article. - Within and post-trial effects of an intensive lifestyle intervention on kidney disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trial.
Knowler WC, Chen H, Bahnson JL, Kahn SE, Lewis CE, Nathan DM, Nelson RG, Pilla SJ, Bantle JP; Look AHEAD Research Group. Knowler WC, et al. BMJ Open Diabetes Res Care. 2024 May 30;12(3):e004079. doi: 10.1136/bmjdrc-2024-004079. BMJ Open Diabetes Res Care. 2024. PMID: 38816203 Free PMC article. Clinical Trial.
References
- Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabets on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
- Diabetes Control and Complications Trial (DCCT) Research Group Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–1720. - PubMed
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy [published correction appears in N Engl J Med. 2000;342:1376] N Engl J Med. 2000;342:381–389. - PubMed
- Molitch ME, Steffes MW, Cleary PA, Nathan DM, the Diabetes Control and Complications Trial Research Group Baseline analysis of renal function in the Diabetes Control and Complications Trial [published correction appears in Kidney Int. 1993;43:1196] Kidney Int. 1993;43:668–674. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical